Together, these two phase III trials demonstrate that aggressive local ablation—delivered either upfront to all macroscopic disease or focally to the thorax—can delay resistance and translate into tangible survival gains when paired with first- or third-generation EGFR-TKIs, thereby establishing a rationale for incorporating LAT into frontline targeted therapy strategies for oncogene-addicted NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.